...that no longer respond to standard-of-care treatments. Its CEO, Claire Mazumdar, has prior experience at Rheos Medicines Inc....

...hired Laurence Turka as CSO, a new position. He co-founded and served as CSO of Rheos Medicines Inc....

...to attract its first major deal less than two years after launch. On Dec. 19, Rheos Medicines Inc....
...to systematically uncover the physiological links between metabolism of immune cells and disease.” Lauren Martz, Senior Editor Rheos Medicines Inc. AutoImmune...

...the partners may share worldwide development and U.S. commercialization rights to certain products. Lauren Martz, Associate Editor Rheos Medicines Inc. AutoImmune...

...Inc. (NASDAQ:TBPH). BlackThorn is a computational sciences company developing therapies for neurobehavioral disorders. Immunometabolism company Rheos Medicines Inc....
...ocular disease company has begun to explore strategic alternatives, including a possible sale. BioCentury Staff BlackThorn Therapeutics Inc. Rheos Medicines Inc. Kintai...

...Curatolo was head of commercial U.S. at NLS Pharma Group (Stans, Switzerland). Cellular metabolism company Rheos Medicines Inc....

...Immunometabolism company Rheos Medicines Inc. (Cambridge, Mass.) hired Sanjay Keswani as CEO. He was SVP and global head...

...Management to develop glutamine antagonists to treat cancer. Two days later, Third Rock Ventures brought Rheos Medicines Inc....
...Ecto-5'-nucleotidase (CD73; NT5E) Preclin Ideaya Biosciences Inc. IDO Aryl hydrocarbon receptor (AHR) Preclin $140 2015 Rheos Medicines Inc....
...NASDAQ:INCY), Wilmington, Del. Kyn Therapeutics Inc., Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Rheos Medicines Inc....

...Immuno-metabolism company Rheos Medicines Inc. (Cambridge, Mass.) emerged from stealth mode with a $60 million series A round...
...transcriptional and metabolomic profiling data sets derived from human immune cell samples. Rheos Medicines Inc., Cambridge, Mass. Chris Lieu Rheos Medicines Inc....

...Third Rock Ventures is taking a page from cancer and Orphan diseases by launching Rheos Medicines Inc. to...
...of its companies when they go public (see BioCentury, Jan. 25, 2016) . Chris Lieu, Staff Writer Rheos Medicines Inc. Third...